contractpharmaSeptember 12, 2018
Tag: Therapeutic agent for protein
WuXi Biologics and Inhibrx, Inc. have entered into an exclusive partnership for the GMP manufacture of certain Inhibrx's protein-based therapeutics.
Inhibrx use WuXi Biologics for GMP manufacturing of its human biologic therapeutics for all projects to be initiated within next three years, during which Inhibrx plans to initiate clinical trials outside of China.
"We have a very strong working relationship with WuXi Biologics. Over the last two years, WuXi Biologics has executed well on our programs and delivered excellent results, enabling GMP manufacturing of one biologic initiating a Phase 1 clinical study in October and four additional biologics for which IND submission is expected over the next year," said Mark Lappe, chief executive officer of Inhibrx. "This partnership supports our immediate and long-term objectives in developing and commercializing our diverse pipeline. We look forward to working with WuXi Biologics to bring optimized therapeutics to underserved patient populations."
"We are excited about this exclusive partnership, one of the largest in the industry. WuXi Biologics has been well recognized as a global leader in the development and manufacturing of biologics and we are very excited about Inhibrx's large and diverse pipeline," said Dr. Chris Chen, chief executive officer of WuXi Biologics. "This agreement exemplifies our unparalleled capacity in global biologics development and manufacturing. We are able to initiate 60 IND-enabling programs and 3 BLA-enabling programs per year, with support from one of the largest biologics development teams in the industry, composed of approximately 1,900 scientists. With globally recognized technical capabilities and unparalleled capacities, we are transforming how biologics are developed in the global setting."
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: